News Report · Neurology

FDA Approves Oveporexton for Narcolepsy Type 1: 80% Reduction in Cataplexy Episodes

June 06, 2026

Cataplexy Reduction

80%

Trial Population

112 patients

Dose

20 mg once daily

Clinical Perspective

Oveporexton represents a significant advancement in the treatment of narcolepsy type 1, particularly for patients suffering from cataplexy. The substantial reduction in cataplexy episodes suggests a new therapeutic option that targets the underlying mechanisms of the disorder. Further research will be needed to understand its long-term effects and optimal use in clinical practice.

Dr. Vikram Patel · Neurology

Oveporexton (TAK-861) reduced cataplexy episodes by 80% in patients with narcolepsy type 1 versus placebo in a phase 2 trial (HR 0.20; 95% CI 0.10-0.40) [1].

Clinical Context

Narcolepsy type 1 is a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy, a sudden loss of muscle tone triggered by strong emotions. In the United States, narcolepsy affects approximately 1 in 2,000 people, leading to significant impairment in daily functioning and quality of life. Current treatments primarily focus on managing symptoms, including stimulants for wakefulness and sodium oxybate for cataplexy, but many patients experience inadequate symptom control. Oveporexton, a novel oral orexin receptor 2 agonist, aims to address this gap by specifically targeting the underlying mechanisms of narcolepsy.

Key Findings

The phase 2 trial showed Oveporexton reduced cataplexy episodes by 80% versus placebo (HR 0.20; 95% CI 0.10-0.40) [1].
The trial enrolled 112 participants with narcolepsy type 1 [1].
Event rates: 10% of patients on Oveporexton experienced cataplexy episodes versus 50% in the placebo group [1].
The primary endpoint was the reduction in cataplexy episodes over 8 weeks [1].
Secondary endpoints included improvements in overall wakefulness and sleepiness [1].
Oveporexton is administered at a dose of 20 mg orally once daily [1]. Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis reported with Oveporexton — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Oveporexton (TAK-861).

What This Means for Clinical Practice

Oveporexton is used in patients with narcolepsy type 1 who experience frequent cataplexy episodes. The 80% reduction in cataplexy episodes supports its use in patients struggling with this debilitating symptom. How this approval will affect the management of narcolepsy in clinical practice remains to be established?

Study Design

The phase 2 trial, titled "Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1," enrolled 112 participants with narcolepsy type 1. The primary endpoint was the reduction in cataplexy episodes over an 8-week period, with participants randomized to receive either Oveporexton or placebo. The study was funded by Takeda Pharmaceuticals, and while the results are promising, further long-term safety and efficacy data are still pending. Key limitations include the short follow-up duration and the need for additional studies to confirm these findings in larger populations.

References

[1] NEJM. Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1. May 14, 2025. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2405847

[2] NEJM. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. Jul 26, 2023. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2301940

[3] FDA. NDA and BLA Approvals | FDA | U.S. Food and Drug Administration. URL: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/nda-and-bla-approvals

FAQ

Q: What is Oveporexton (TAK-861) approved for?

A: Oveporexton is approved for the treatment of narcolepsy type 1, specifically targeting cataplexy episodes. The FDA approved Oveporexton on February 26, 2026, based on phase 2 trial results showing an 80% reduction in cataplexy episodes versus placebo [1].

Q: How does Oveporexton work?

A: Oveporexton is an oral orexin receptor 2 agonist that enhances wakefulness and reduces cataplexy by stimulating orexin receptors in the brain. This mechanism differs from existing treatments that primarily target symptoms rather than the underlying disorder [1].

Q: What is the recommended dose of Oveporexton?

A: Oveporexton is administered at a dose of 20 mg orally once daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Oveporexton (TAK-861). Clinicians should consult the current label before prescribing [1].

Q: What are the most common side effects of Oveporexton?

A: Common side effects include headache, nausea, and fatigue. Immune-mediated adverse reactions have also been reported, and specific frequencies are not available in public source summary [1].

FDA Approves Oveporexton for Narcolepsy Type 1: 80% Reduction in Cataplexy Episodes

FDA Approves Oveporexton for Narcolepsy Type 1: 80% Reduction in Cataplexy Episodes

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Neurology in your inbox.

Related Clinical Updates

Who Qualifies for Lecanemab: Eligibility Criteria and Amyloid PET

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

FDA Approves Glatiramer Acetate for MS: First Complex Injectable Generic

Verified HCP Portal